Victoria Clarke
Nurse Practitioner · Haddon Heights, NJNPI 1366945214
Payments from drug & device makers
Across 125 payments — averaging $32.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$2K
- AstraZeneca$327
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$282
- Novartis$261
- Pfizer$186
- Impulse Dynamics (USA) Inc.$164
- plus $325 from 10 others
What the payments were for
- Food & beverage$4,042100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 52 | $2,498 |
| AstraZeneca | 8 | $327 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $282 |
| Novartis | 21 | $261 |
| Pfizer | 12 | $186 |
| Impulse Dynamics (USA) Inc. | 7 | $164 |
| Johnson & Johnson | 6 | $88 |
| Bayer | 2 | $46 |
| Philips North America LLC | 2 | $34 |
| W. L. Gore & Associates, Inc. | 2 | $31 |
| Merck | 2 | $29 |
| Novo Nordisk | 2 | $28 |
| Inspire Medical Systems, Inc. | 1 | $22 |
| Scpharmaceuticals Inc. | 1 | $18 |
| Amgen | 1 | $16 |
| Daiichi Sankyo Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AVEIR$609
- ENSITE$143
- AMPLATZER$128
- Fortify Assura, Ellipse ICD$116
- Perclose ProStyle$106
How this compares
$4,042 in reported general payments places this provider in the 90th percentile of 2,138 nurse practitioner providers in New Jersey.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 57 | $74,144 |
| BrilintaTicagrelor | 41 | $28,091 |
| XareltoRivaroxaban | 15 | $22,624 |
| EntrestoSacubitril/Valsartan | 22 | $20,314 |
| FarxigaDapagliflozin Propanediol | 20 | $16,525 |
| Metoprolol Succinate | 136 | $2,806 |
| Rosuvastatin Calcium | 116 | $2,235 |
| Atorvastatin Calcium | 117 | $1,427 |
| Carvedilol | 67 | $989 |
| Valsartan | 31 | $959 |
| Ezetimibe | 24 | $858 |
| ClopidogrelClopidogrel Bisulfate | 41 | $831 |
| Amlodipine Besylate | 53 | $770 |
| Furosemide | 72 | $536 |
| Metoprolol Tartrate | 37 | $520 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $186 | $74,14457 claims |
| AstraZenecaBrilinta, Farxiga | $327 | $44,61661 claims |
| Johnson & JohnsonXarelto | $88 | $22,62415 claims |
| NovartisEntresto | $261 | $20,31422 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,138 nurse practitioner providers in New Jersey.
Other nurse practitioner in Haddon Heights
- Janice BeitzHaddon Heights$75K
- Nancy BonnetMorristown$407K
- Vanessa CoppolaCloster$205K
- Olufunmilayo IloriUnion$133K
- Adewale AdefowojuUnion$70K
- Sophia KimEnglewood$70K
- Elizabeth FletcherCamden$62K
- Lannae EwingLinwood$39K
- Beth SavageNew Brunswick$34K
- Tina OcchiutoMorristown$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.